Cargando…
Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model
BACKGROUND: To compare the efficacy of low dose (27 mg) Bacillus Calmette-Guérin (BCG) and a full dose (81 mg) BCG immunotherapy for patients with intermediate and high-risk non-muscle invasive bladder cancer (NMIBC) after a typical transurethral bladder resection. METHODS: We constructed a Markov m...
Autores principales: | Wang, Zongren, Xiao, Han, Wei, Guangyan, Zhang, Ning, Wei, Mengchao, Chen, Zebin, Peng, Zhenwei, Peng, Sui, Qiu, Shaopeng, Li, Heping, Long, Jianting |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233591/ https://www.ncbi.nlm.nih.gov/pubmed/30419836 http://dx.doi.org/10.1186/s12885-018-4988-z |
Ejemplares similares
-
Goldilocks and the BCG: Bacillus Calmette-Guérin Dose Reduction in the Age of Shortage
por: Nikas, Christine V., et al.
Publicado: (2020) -
Evaluation of the Dwell-Time and Dose Difference in Intravesical Bacillus Calmette-Guèrin Therapy
por: Nagai, Takashi, et al.
Publicado: (2019) -
Bacillus Calmette–Guérin Immunotherapy for Cancer
por: Cardillo, Fabíola, et al.
Publicado: (2021) -
Predictive biomarkers of response to bacillus Calmette‐Guérin immunotherapy and bacillus Calmette‐Guérin failure for non‐muscle invasive bladder cancer
por: Wang, Ziting, et al.
Publicado: (2022) -
VARIABILITY OF BCG STRAINS (BACILLUS CALMETTE-GUÉRIN)
por: Suter, W. Emanuel, et al.
Publicado: (1951)